Domain, Versant Score Exit At Clovis Oncology

Two, Southern California venture investors have scored an exit this morning with the IPO of Clovis Oncology. San Diego's Domain Associates and Newport Beach-based Versant Ventures are both significant investors in Clovis, which priced its IPO last night at $13.00, at the lower end of its $13.00 to $15.00 estimated IPO range. Clovis will start trading today on the NASDAQ Global Select Market as CLVS. Clovis was venture backed by Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, and Abingworth Bioventures, along with Pfizer. Prior to the IPO, Domain owned 18.5 percent of Clovis, and Versant owned 7.8 percent.